A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Bristol-Myers Squibb
Bristol-Myers Squibb
Seagen Inc.
Eli Lilly and Company
NeoImmuneTech
Verastem, Inc.
Essen Biotech
City of Hope Medical Center
Takeda
Eli Lilly and Company
VM Oncology, LLC
Eli Lilly and Company
Trishula Therapeutics, Inc.
Trishula Therapeutics, Inc.
DEKA Biosciences
Intensity Therapeutics, Inc.
Merck Sharp & Dohme LLC
Carisma Therapeutics Inc
Eli Lilly and Company
NGM Biopharmaceuticals, Inc
ADC Therapeutics S.A.
Eli Lilly and Company
NGM Biopharmaceuticals, Inc
Celldex Therapeutics
Ikena Oncology
Corvus Pharmaceuticals, Inc.
Fate Therapeutics
Kineta Inc.
M.D. Anderson Cancer Center
Fate Therapeutics
Xencor, Inc.
Incyte Corporation
Gary Onik MD
Western Regional Medical Center
NHS Greater Glasgow and Clyde